REDWOOD CITY, Calif.--(BUSINESS WIRE)--Genelabs Technologies, Inc. (Nasdaq:GNLB - News), a biopharmaceutical company focused on discovering novel compounds for hepatitis, reported fourth quarter and year-end financial results for 2007. The Company also provided a 2008 outlook on its priorities for advancing its pipeline of hepatitis C virus (HCV) inhibitors.
